Johnson & Johnson (NYSE:JNJ) Shares Bought by Peterson Wealth Services

Peterson Wealth Services lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,982 shares of the company's stock after purchasing an additional 1,871 shares during the period. Peterson Wealth Services' holdings in Johnson & Johnson were worth $2,485,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of JNJ. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $33,000. Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Bank of America upped their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $172.87.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $3.54 during midday trading on Tuesday, reaching $167.90. 9,277,637 shares of the stock were exchanged, compared to its average volume of 8,146,116. The business's 50-day moving average price is $154.29 and its 200 day moving average price is $155.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market capitalization of $403.99 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 2.08 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.